Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein
- PMID: 8923465
- DOI: 10.1210/mend.10.11.8923465
Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein
Abstract
To better understand structure-activity relationships in the human estrogen receptor (ER), we examined the role of tyrosine 537 in the transcriptional response of the receptor, since this residue is close to a region of the hormone-binding domain shown previously to be important in hormone-dependent transcriptional activity and because this amino acid has been proposed to be a tyrosine kinase phosphorylation site important in the activity of the ER. We substituted five amino acids at this position (alanine, phenylalanine, glutamic acid, lysine, or serine) and screened these mutants for their biological activities in the presence and absence of estradiol. Two of the ER mutants, Y537A and Y537S, displayed estrogen-independent constitutive activity that was approximately 20% or 100%, respectively, of the activity of the wild type receptor with estradiol, when assessed in two different cell backgrounds using three different estrogen-responsive promoters. In some circumstances, the Y537E and Y537K proteins also exhibited some low level of constitutive activity. The constitutive activity of the mutants, as well as their activity in the presence of E2, was fully suppressed by antiestrogen. The extent of interaction of the constitutively active ERs with the steroid receptor coactivator-1 (SRC-1) closely parallel the magnitude of transcriptional activity of the receptor. Whereas wild type ER showed interaction with SRC-1 only in the presence of estrogen, Y537A and Y537S ER showed moderate or full interaction in the absence of ligand, an interaction that was blocked by antiestrogen, and the magnitude of interaction was increased to or remained at 100% upon estradiol treatment, implying that the ability of an ER to associate with SRC-1 is a good indicator of a transcriptionally active conformational state of the receptor. Our findings indicate that tyrosine 537 is in a region important in the ligand regulation of ER transcriptional activity and that the presence of certain amino acids at this position can shift ER into a conformation that is active even without ligand. However, tyrosine is not required at this site for estrogen binding or transcriptional response to estrogen in the systems investigated. Our findings, interpreted in light of the recently published x-ray crystal structure of the ligand-binding domains of three related receptors of the nuclear receptor superfamily, suggest that some of the amino acid substitutions introduced at position 537 may facilitate the shift of helix 12 of the ER into an active conformation and/or allow for differential stabilization of the receptor in its active form.
Similar articles
-
Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes.Mol Endocrinol. 1997 Aug;11(9):1375-86. doi: 10.1210/mend.11.9.9983. Mol Endocrinol. 1997. PMID: 9259327
-
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction.Biochemistry. 1997 Dec 2;36(48):14897-905. doi: 10.1021/bi971746l. Biochemistry. 1997. PMID: 9398213
-
Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.Mol Endocrinol. 1999 Nov;13(11):1912-23. doi: 10.1210/mend.13.11.0373. Mol Endocrinol. 1999. PMID: 10551784
-
William L. McGuire Memorial Symposium. Estrogen receptors: ligand discrimination and antiestrogen action.Breast Cancer Res Treat. 1993;27(1-2):17-26. doi: 10.1007/BF00683190. Breast Cancer Res Treat. 1993. PMID: 8260727 Review.
-
Hormone binding and transcription activation by estrogen receptors: analyses using mammalian and yeast systems.J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):39-48. doi: 10.1016/0960-0760(93)90055-2. J Steroid Biochem Mol Biol. 1993. PMID: 8274440 Review.
Cited by
-
Antiestrogens: structure-activity relationships and use in breast cancer treatment.J Mol Endocrinol. 2017 Jan;58(1):R15-R31. doi: 10.1530/JME-16-0024. Epub 2016 Oct 11. J Mol Endocrinol. 2017. PMID: 27729460 Free PMC article. Review.
-
Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.J Natl Cancer Inst. 2015 Apr 2;107(6):djv075. doi: 10.1093/jnci/djv075. Print 2015 Jun. J Natl Cancer Inst. 2015. PMID: 25838462 Free PMC article.
-
Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.Breast Cancer Res Treat. 2019 Feb;173(3):489-497. doi: 10.1007/s10549-018-5023-4. Epub 2018 Nov 1. Breast Cancer Res Treat. 2019. PMID: 30382472 Free PMC article. Review.
-
18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-α Mutations in Breast Cancer.J Nucl Med. 2019 Sep;60(9):1247-1252. doi: 10.2967/jnumed.118.224667. Epub 2019 Mar 8. J Nucl Med. 2019. PMID: 30850489 Free PMC article.
-
Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics.Mol Cell Biol. 1997 Aug;17(8):4644-53. doi: 10.1128/MCB.17.8.4644. Mol Cell Biol. 1997. PMID: 9234721 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous